Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL.
Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Dacarbazine; Female; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Quality of Life; Remission Induction; Survival Analysis
Patients aged ≥60 years with treatment-naive Hodgkin lymphoma (HL) have few treatment options and inferior survival due to treatment-related toxicities and comorbidities. This phase 2, nonrandomized, open-label study evaluated brentuximab vedotin (BV) monotherapy (results previously reported), BV plus dacarbazine (DTIC), and BV plus bendamustine. Patients had classical HL and were ineligible for or declined frontline chemotherapy. Twenty-two patients received 1.8 mg/kg BV and 375 mg/m
Friedberg, Jonathan W; Forero-Torres, Andres; Bordoni, Rodolfo E; Cline, Vivian J M; Patel Donnelly, Dipti; Flynn, Patrick J; Olsen, Gregg; Chen, Robert; Fong, Abraham; Wang, Yinghui; and Yasenchak, Christopher A, "Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL." (2017). Articles, Abstracts, and Reports. 1760.